{"success":true,"data":{"pressRelease":{"id":"162027","rtpr_id":"nNFC7lMScj-20261006","ticker":"ADIA","exchange":"OTC","all_tickers":["ADIA"],"title":"Adia Med Partners with Live Oak Health (dba QCM Biologics) as Distributor and Sells 30% Stake in Adia Labs for $1.5 Million","author":"Newsfile Corp","published_at":"2026-10-06T13:19:49.511Z","article_body":"Winter Park, Florida--(Newsfile Corp. - October 6, 2026) - Adia Med Inc.\n(OTCQB: ADIA) today announced that it has sold a 30% interest in Adia Labs LLC\nto Live Oak Health, a stem cell distributor doing business as QCM Biologics,\nfor $1.5 million, and that the sale is paired with a distribution partnership.\nThe Company has filed a Form 8-K related to the transaction.\n\nLink to Form 8-K here: Inline Viewer: ADIA MED, INC. 8-K 2026-09-30\n(https://api.newsfilecorp.com/redirect/jNJpMfan3e)\n\nThe transaction includes $1.0 million in cash and a $500,000 promissory note\npayable to Adia Labs. Following the sale, Adia Med retains a 70% ownership\ninterest in Adia Labs. Live Oak Health also received a two-year option to\nacquire an additional 10% stake in Adia Labs for $500,000.\n\nUnder the related distribution arrangement, QCM Biologics becomes another\ndistributor of Adia Labs products and will sell those products through its\nexisting sales force. Because Live Oak Health is acquiring an ownership\ninterest in Adia Labs, the arrangement provides that it will buy exclusively\nfrom Adia Labs for all products it distributes under the partnership. Adia Med\nsaid the deal is intended to add an outside distribution channel rather than\nrequire the Company to build that coverage internally.\n\n\"We wanted a distributor with money in the business, not just a purchase\norder,\" said Larry Powalisz, Chief Executive Officer of Adia Med. \"QCM comes\nin as a part owner and as another distributor, and the cash goes to Adia Labs.\nThe option is there if Live Oak Health wants a larger stake.\"\n\nAdia Labs products, including AdiaVita, are not FDA-approved to diagnose,\ntreat, cure, or prevent any disease.\n\nThe Company's Form 8-K related to the transaction is available at www.sec.gov.\n\nFor questions, inquiries, or additional information, please contact Larry\nPowalisz at ceo@adiamed.com or by phone at 321-231-2843.\n\nAbout Adia Med Inc.\n\nAdia Med Inc. (OTCQB: ADIA), headquartered in Winter Park, Florida, is a\nregenerative medicine company built around active, IRB-approved stem cell\ntherapy studies. Through its Adia Med clinics, the company delivers stem cell\ntreatments alongside complementary services like platelet-rich plasma (PRP),\ntherapeutic plasma exchange (TPE), and autologous hematopoietic stem cell\ntransplantation (aHSCT), supported by multiple Institutional Review Board\n(IRB)-approved clinical studies, The current studies are targeting autism\nspectrum disorder, chronic kidney disease, and lower back pain, with more\nplanned for 2026. Its Adia Labs division manufactures regenerative products\n(AdiaVita, AdiaLink) that supply this clinical work.\n\nAdia Labs generates revenue by manufacturing and selling regenerative products\n(AdiaVita and AdiaLink) to Adia Med clinics and external providers. Adia Med\nclinics generate revenue through patient treatments (stem cell therapies, PRP,\nTPE, and aHSCT). Additional revenue comes from the company's 18% equity stake\nin Cement Factory LLC and from ADIA Life LLC's wellness product distribution.\n\nWebsite: www.adiamed.com\nWebsite: www.adialabs.com\nWebsite: www.cementfactory.co\nTwitter (X): @adia_med\nInstagram: @adia_med\nFacebook: @adia_med\n\nSafe Harbor: This Press Release contains forward-looking statements within the\nmeaning of Section 27A of the Securities Act of 1933 and Section 21E of the\nSecurities Exchange Act of 1934. These forward-looking statements are based on\nthe current plans and expectations of management and are subject to a few\nuncertainties and risks that could significantly affect the company's current\nplans and expectations, as well as future results of operations and financial\ncondition. A more extensive listing of risks and factors that may affect the\ncompany's business prospects and cause actual results to differ materially\nfrom those described in the forward-looking statements can be found in the\nreports and other documents filed by the company with the Securities and\nExchange Commission and OTC Markets, Inc. OTC Disclosure and News Service. The\ncompany undertakes no obligation to publicly update or revise any\nforward-looking statements, because of new information, future events or\notherwise.\n\nTo view the source version of this press release, please visit\nhttps://www.newsfilecorp.com/release/317634","article_body_html":"","raw_payload":{"data":{"id":"nNFC7lMScj-20261006","title":"Adia Med Partners with Live Oak Health (dba QCM Biologics) as Distributor and Sells 30% Stake in Adia Labs for $1.5 Million","author":"Newsfile Corp","ticker":"ADIA","created":"2026-10-06T13:19:49.511Z","tickers":["ADIA"],"exchange":"OTC","article_body":"Winter Park, Florida--(Newsfile Corp. - October 6, 2026) - Adia Med Inc.\n(OTCQB: ADIA) today announced that it has sold a 30% interest in Adia Labs LLC\nto Live Oak Health, a stem cell distributor doing business as QCM Biologics,\nfor $1.5 million, and that the sale is paired with a distribution partnership.\nThe Company has filed a Form 8-K related to the transaction.\n\nLink to Form 8-K here: Inline Viewer: ADIA MED, INC. 8-K 2026-09-30\n(https://api.newsfilecorp.com/redirect/jNJpMfan3e)\n\nThe transaction includes $1.0 million in cash and a $500,000 promissory note\npayable to Adia Labs. Following the sale, Adia Med retains a 70% ownership\ninterest in Adia Labs. Live Oak Health also received a two-year option to\nacquire an additional 10% stake in Adia Labs for $500,000.\n\nUnder the related distribution arrangement, QCM Biologics becomes another\ndistributor of Adia Labs products and will sell those products through its\nexisting sales force. Because Live Oak Health is acquiring an ownership\ninterest in Adia Labs, the arrangement provides that it will buy exclusively\nfrom Adia Labs for all products it distributes under the partnership. Adia Med\nsaid the deal is intended to add an outside distribution channel rather than\nrequire the Company to build that coverage internally.\n\n\"We wanted a distributor with money in the business, not just a purchase\norder,\" said Larry Powalisz, Chief Executive Officer of Adia Med. \"QCM comes\nin as a part owner and as another distributor, and the cash goes to Adia Labs.\nThe option is there if Live Oak Health wants a larger stake.\"\n\nAdia Labs products, including AdiaVita, are not FDA-approved to diagnose,\ntreat, cure, or prevent any disease.\n\nThe Company's Form 8-K related to the transaction is available at www.sec.gov.\n\nFor questions, inquiries, or additional information, please contact Larry\nPowalisz at ceo@adiamed.com or by phone at 321-231-2843.\n\nAbout Adia Med Inc.\n\nAdia Med Inc. (OTCQB: ADIA), headquartered in Winter Park, Florida, is a\nregenerative medicine company built around active, IRB-approved stem cell\ntherapy studies. Through its Adia Med clinics, the company delivers stem cell\ntreatments alongside complementary services like platelet-rich plasma (PRP),\ntherapeutic plasma exchange (TPE), and autologous hematopoietic stem cell\ntransplantation (aHSCT), supported by multiple Institutional Review Board\n(IRB)-approved clinical studies, The current studies are targeting autism\nspectrum disorder, chronic kidney disease, and lower back pain, with more\nplanned for 2026. Its Adia Labs division manufactures regenerative products\n(AdiaVita, AdiaLink) that supply this clinical work.\n\nAdia Labs generates revenue by manufacturing and selling regenerative products\n(AdiaVita and AdiaLink) to Adia Med clinics and external providers. Adia Med\nclinics generate revenue through patient treatments (stem cell therapies, PRP,\nTPE, and aHSCT). Additional revenue comes from the company's 18% equity stake\nin Cement Factory LLC and from ADIA Life LLC's wellness product distribution.\n\nWebsite: www.adiamed.com\nWebsite: www.adialabs.com\nWebsite: www.cementfactory.co\nTwitter (X): @adia_med\nInstagram: @adia_med\nFacebook: @adia_med\n\nSafe Harbor: This Press Release contains forward-looking statements within the\nmeaning of Section 27A of the Securities Act of 1933 and Section 21E of the\nSecurities Exchange Act of 1934. These forward-looking statements are based on\nthe current plans and expectations of management and are subject to a few\nuncertainties and risks that could significantly affect the company's current\nplans and expectations, as well as future results of operations and financial\ncondition. A more extensive listing of risks and factors that may affect the\ncompany's business prospects and cause actual results to differ materially\nfrom those described in the forward-looking statements can be found in the\nreports and other documents filed by the company with the Securities and\nExchange Commission and OTC Markets, Inc. OTC Disclosure and News Service. The\ncompany undertakes no obligation to publicly update or revise any\nforward-looking statements, because of new information, future events or\notherwise.\n\nTo view the source version of this press release, please visit\nhttps://www.newsfilecorp.com/release/317634"},"type":"article","timestamp":"2026-10-06T13:19:49.553838202Z","server_sent_at_ms":1791292789553},"received_at":"2026-10-06T13:19:49.605Z","source_url":"https://www.newsfilecorp.com/release/317634"},"analysis":{"id":"150529","press_release_id":"162027","analysis_json":{"industry":{"label":"Health Care Providers & Services","sector":"Health Care"},"redFlags":["half of consideration is a $500,000 promissory note, not cash","option could further dilute Adia Med's ownership of its revenue-generating subsidiary","products not FDA-approved to diagnose, treat, cure, or prevent any disease"],"eventType":"m_and_a","narrative":"Adia Med sold a 30% stake in its Adia Labs subsidiary to Live Oak Health (dba QCM Biologics) for $1.5 million, structured as $1.0 million cash plus a $500,000 promissory note.\n\nThe deal includes a two-year option for Live Oak to buy an additional 10% for $500,000, and pairs the sale with an exclusive distribution arrangement under which QCM Biologics sells Adia Labs products through its existing sales force.\n\nThe transaction adds an external distribution channel without internal build-out costs, though half the consideration is a note rather than cash and the proceeds go to Adia Labs rather than the parent.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Micro-cap sells 30% of subsidiary with exclusive distribution partner attached — modest cash infusion, part-promissory consideration."},"keyFigures":{"dealValueUsd":1500000,"customDimensions":{"option_terms":"two-year option to acquire additional 10% stake for $500,000","cash_component":1000000,"stake_sold_pct":30,"promissory_note":500000,"retained_ownership_pct":70}},"quotedText":"We wanted a distributor with money in the business, not just a purchase order","namedEntities":{"people":[{"name":"Larry Powalisz","role":"CEO"}],"products":["AdiaVita","AdiaLink"],"companies":[{"name":"Adia Med Inc.","ticker":"ADIA","relationship":"filer/seller"},{"name":"Live Oak Health (dba QCM Biologics)","relationship":"buyer and distribution partner"},{"name":"Adia Labs LLC","relationship":"subsidiary (30% stake sold)"},{"name":"Cement Factory LLC","relationship":"equity stake held by filer"}],"dollarAmounts":[{"amount":"$1.5 million","context":"sale of 30% interest in Adia Labs"},{"amount":"$1.0 million","context":"cash component of transaction"},{"amount":"$500,000","context":"promissory note payable to Adia Labs"},{"amount":"$500,000","context":"option price for additional 10% stake"}]},"materialImpact":{"score":2,"reasoning":"Small-cap partial divestiture of a 30% stake in a subsidiary for $1.5M paired with a distribution deal. Material to this micro-cap but modest in absolute terms."},"tickerRelevance":{"others":[],"primary":"ADIA"},"globalImportance":15,"audienceRelevance":10,"eventTypeSecondary":["partnership"],"importanceComponents":{"tickerTier":"micro-cap OTCQB","eventGravity":"small subsidiary stake sale plus distribution deal","householdBrandBoost":0}},"event_type":"m_and_a","event_type_secondary":["partnership"],"sentiment":"neutral","material_impact_score":2,"narrative":"Adia Med sold a 30% stake in its Adia Labs subsidiary to Live Oak Health (dba QCM Biologics) for $1.5 million, structured as $1.0 million cash plus a $500,000 promissory note.\n\nThe deal includes a two-year option for Live Oak to buy an additional 10% for $500,000, and pairs the sale with an exclusive distribution arrangement under which QCM Biologics sells Adia Labs products through its existing sales force.\n\nThe transaction adds an external distribution channel without internal build-out costs, though half the consideration is a note rather than cash and the proceeds go to Adia Labs rather than the parent.","key_figures":{"dealValueUsd":1500000,"customDimensions":{"option_terms":"two-year option to acquire additional 10% stake for $500,000","cash_component":1000000,"stake_sold_pct":30,"promissory_note":500000,"retained_ownership_pct":70}},"named_entities":{"people":[{"name":"Larry Powalisz","role":"CEO"}],"products":["AdiaVita","AdiaLink"],"companies":[{"name":"Adia Med Inc.","ticker":"ADIA","relationship":"filer/seller"},{"name":"Live Oak Health (dba QCM Biologics)","relationship":"buyer and distribution partner"},{"name":"Adia Labs LLC","relationship":"subsidiary (30% stake sold)"},{"name":"Cement Factory LLC","relationship":"equity stake held by filer"}],"dollarAmounts":[{"amount":"$1.5 million","context":"sale of 30% interest in Adia Labs"},{"amount":"$1.0 million","context":"cash component of transaction"},{"amount":"$500,000","context":"promissory note payable to Adia Labs"},{"amount":"$500,000","context":"option price for additional 10% stake"}]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:5c812bd9e28b810d","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-06T13:19:56.551Z","global_importance":15,"audience_relevance":10,"importance_components":{"tickerTier":"micro-cap OTCQB","eventGravity":"small subsidiary stake sale plus distribution deal","householdBrandBoost":0}},"durationMs":6930,"modelName":"glm-5.3-flashx"}}